Publications & Articles
Select peer-reviewed papers, invited articles and media features highlighting work in viral vector analytics and gene therapy development.
Peer-reviewed Publications
Study outlining a formulation development workflow for lentiviral vectors used in gene and cell therapy manufacturing.
Physical characterization and stabilization of a lentiviral vector against adsorption and freeze-thaw. J Pharm Sci (2018).
Analytical method for quantifying infectious titer of lentiviral vectors, designed for high-throughput screening applications.
Design of a titering assay for lentiviral vectors utilizing direct extraction of DNA from transduced cells in microtiter plates. Mol Ther Methods Clin Dev (2016).
Workflow for developing a replication-competent lentivirus (RCL) assay tailored for non-VSV-G pseudotyped vector systems.
Development of a replication-competent lentivirus (RCL) assay for testing HIV-1 based vectors pseudotyped with a modified alphavirus envelope. Mol Ther Methods Clin Dev (2015).
Preclinical evaluation demonstrating safety and performance of a next-generation lentiviral vector platform.
Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy. J Immunother (2015).
Characterization of a dendritic-cell-targeted lentiviral vector designed for improved gene delivery specificity.
Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells. Mol Ther (2014).
Analysis of lentiviral vector design modifications that reduce psi-gag recombination during manufacturing.
A rev-independent gag/pol eliminates detectable psi-gag recombination in lentiviral vectors. Biores Open Access (2013).
Invited Articles & Interviews
Overview of an industry-acadmia collaboration accelerating AAV gene therapy development for ultra-rare diseases.
An open-access platform: A NIIMBL approach to gene therapy for rare diseases. The Bridge (2025).
Interview on gene delivery of the future: viral and non-viral vector CMC.
Building scalable, science-forward gene delivery platforms. Cell & Gene Therapy Insights (2025).
Getting in Touch
Have a question or want to explore working together?